lung%20cancer
LUNG CANCER
Lung cancer is having a malignant tumor in the lungs especially in the cells lining air passages.
Primary tumor-related signs and symptoms are cough, dyspnea, hemoptysis, and chest discomfort.
Signs and symptoms due to intrathoracic spread may involve the nerves (hoarseness, dyspnea, muscle wasting of upper limb, Horner's syndrome), chest wall and pleura (chest pain, dyspnea) and vascular structures (facial swelling, dilated neck veins, cardiac tamponade) & viscera (dsyphagia).
The signs and symptoms due to metastatic spread are bone pain with or without pleuritic pain, neurologic symptoms, limb weakness, unsteady gait, cervical lymphadenopathy, and skin nodules.
Drug Information

Indication: Monotherapy treatment of epidermal growth factor receptor (EGFR) TKI-naive w/ locally advanced or metastatic n...

Indication: Unresectable or metastatic melanoma. Advanced non-small cell lung carcinoma (NSCLC) whose tumors express PD-L1...

Indication: Idiopathic pulmonary fibrosis (IPF) in adult.

Indication: 1st-line treatment of adult patients w/ locally advance or metastatic non-small cell lung cancer (NSCLC) whose...

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Indication: Newly diagnosed glioblastoma multiforme concomitantly w/ radiotherapy & adjuvant treatment. Malignant glio...

Indication: Advanced non-small cell lung cancer (NSCLC) whose tumors are anaphylastic lymphoma kinase (ALK) +ve & meta...

Indication: Malignant pleural mesothelioma: In combination w/ cisplatin for chemotherapy-naive patients w/ unresectable ma...

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Alecensa
alectinib

Indication: 1st-line treatment of adult patients w/ anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung...

1  /  6
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.